These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 19852511)

  • 1. Targeted delivery of antisense oligodeoxynucleotide by transferrin conjugated pH-sensitive lipopolyplex nanoparticles: a novel oligonucleotide-based therapeutic strategy in acute myeloid leukemia.
    Jin Y; Liu S; Yu B; Golan S; Koh CG; Yang J; Huynh L; Yang X; Pang J; Muthusamy N; Chan KK; Byrd JC; Talmon Y; Lee LJ; Lee RJ; Marcucci G
    Mol Pharm; 2010 Feb; 7(1):196-206. PubMed ID: 19852511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2.
    Yang X; Koh CG; Liu S; Pan X; Santhanam R; Yu B; Peng Y; Pang J; Golan S; Talmon Y; Jin Y; Muthusamy N; Byrd JC; Chan KK; Lee LJ; Marcucci G; Lee RJ
    Mol Pharm; 2009; 6(1):221-30. PubMed ID: 19183107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD33-Targeted Lipid Nanoparticles (aCD33LNs) for Therapeutic Delivery of GTI-2040 to Acute Myelogenous Leukemia.
    Li H; Xu S; Quan J; Yung BC; Pang J; Zhou C; Cho YA; Zhang M; Liu S; Muthusamy N; Chan KK; Byrd JC; Lee LJ; Marcucci G; Lee RJ
    Mol Pharm; 2015 Jun; 12(6):2010-8. PubMed ID: 25871632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia.
    Huang X; Schwind S; Yu B; Santhanam R; Wang H; Hoellerbauer P; Mims A; Klisovic R; Walker AR; Chan KK; Blum W; Perrotti D; Byrd JC; Bloomfield CD; Caligiuri MA; Lee RJ; Garzon R; Muthusamy N; Lee LJ; Marcucci G
    Clin Cancer Res; 2013 May; 19(9):2355-67. PubMed ID: 23493348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia.
    Klisovic RB; Blum W; Liu Z; Xie Z; Kefauver C; Huynh L; Zwiebel JA; Devine SM; Byrd JC; Grever MR; Chan KK; Marcucci G
    Leuk Lymphoma; 2014 Jun; 55(6):1332-6. PubMed ID: 24015841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delivery of antisense oligodeoxyribonucleotide lipopolyplex nanoparticles assembled by microfluidic hydrodynamic focusing.
    Koh CG; Zhang X; Liu S; Golan S; Yu B; Yang X; Guan J; Jin Y; Talmon Y; Muthusamy N; Chan KK; Byrd JC; Lee RJ; Marcucci G; Lee LJ
    J Control Release; 2010 Jan; 141(1):62-9. PubMed ID: 19716852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia.
    Klisovic RB; Blum W; Wei X; Liu S; Liu Z; Xie Z; Vukosavljevic T; Kefauver C; Huynh L; Pang J; Zwiebel JA; Devine S; Byrd JC; Grever MR; Chan K; Marcucci G
    Clin Cancer Res; 2008 Jun; 14(12):3889-95. PubMed ID: 18559610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transferrin receptor targeted lipopolyplexes for delivery of antisense oligonucleotide g3139 in a murine k562 xenograft model.
    Zhang X; Koh CG; Yu B; Liu S; Piao L; Marcucci G; Lee RJ; Lee LJ
    Pharm Res; 2009 Jun; 26(6):1516-24. PubMed ID: 19291371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical modulation of aracytidine (Ara-C) effects by GTI-2040, a ribonucleotide reductase inhibitor, in K562 human leukemia cells.
    Chen P; Aimiuwu J; Xie Z; Wei X; Liu S; Klisovic R; Marcucci G; Chan KK
    AAPS J; 2011 Mar; 13(1):131-40. PubMed ID: 21191677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Polyethylenimine-Containing and Transferrin-Conjugated Lipid Nanoparticle System for Antisense Oligonucleotide Delivery to AML.
    Yuan Y; Zhang L; Cao H; Yang Y; Zheng Y; Yang XJ
    Biomed Res Int; 2016; 2016():1287128. PubMed ID: 27034925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells.
    Li SD; Huang L
    Mol Pharm; 2006; 3(5):579-88. PubMed ID: 17009857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors.
    Lee Y; Vassilakos A; Feng N; Lam V; Xie H; Wang M; Jin H; Xiong K; Liu C; Wright J; Young A
    Cancer Res; 2003 Jun; 63(11):2802-11. PubMed ID: 12782585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes.
    Chiu SJ; Liu S; Perrotti D; Marcucci G; Lee RJ
    J Control Release; 2006 May; 112(2):199-207. PubMed ID: 16564596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy.
    Guo J; Russell EG; Darcy R; Cotter TG; McKenna SL; Cahill MR; O'Driscoll CM
    Mol Pharm; 2017 Mar; 14(3):940-952. PubMed ID: 28146632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transferrin receptor-targeted liposomes encapsulating anti-BCR-ABL siRNA or asODN for chronic myeloid leukemia treatment.
    Mendonça LS; Firmino F; Moreira JN; Pedroso de Lima MC; Simões S
    Bioconjug Chem; 2010 Jan; 21(1):157-68. PubMed ID: 20000596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coaxial electrohydrodynamic spraying: a novel one-step technique to prepare oligodeoxynucleotide encapsulated lipoplex nanoparticles.
    Wu Y; Yu B; Jackson A; Zha W; Lee LJ; Wyslouzil BE
    Mol Pharm; 2009; 6(5):1371-9. PubMed ID: 19499922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delivery of antisense oligonucleotides to leukemia cells by RNA bacteriophage capsids.
    Wu M; Sherwin T; Brown WL; Stockley PG
    Nanomedicine; 2005 Mar; 1(1):67-76. PubMed ID: 17292060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of telomerase activity with hTERT antisense increases the effect of CDDP-induced apoptosis in myeloid leukemia.
    Yuan Z; Mei HD
    Hematol J; 2002; 3(4):201-5. PubMed ID: 12189566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A microfluidic method to synthesize transferrin-lipid nanoparticles loaded with siRNA LOR-1284 for therapy of acute myeloid leukemia.
    Yang Z; Yu B; Zhu J; Huang X; Xie J; Xu S; Yang X; Wang X; Yung BC; Lee LJ; Lee RJ; Teng L
    Nanoscale; 2014 Aug; 6(16):9742-51. PubMed ID: 25003978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-targeted and pH-controlled delivery of doxorubicin using gold nanorods for lung cancer therapy.
    Amreddy N; Muralidharan R; Babu A; Mehta M; Johnson EV; Zhao YD; Munshi A; Ramesh R
    Int J Nanomedicine; 2015; 10():6773-88. PubMed ID: 26604751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.